Privi Speci.Q1 FY27
Privi Speci. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹3,444P/E: 38.9Market Cap: ₹13.6K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →The company targets achieving Rs. 5,000 crore in revenue and over Rs. 1,000 crore in EBITDA within the next 3-4 years, representing approximately 2x growth.
- →They expect a 20% CAGR in revenue while maintaining similar EBITDA margins.
- →Capacity expansions from 48,000 metric tons to 66,000 metric tons by September 2027 will support growth.
- →New specialty molecules including those based on furfural (from corn cob) will add about Rs. 1,000 crore+ to revenue.
- →The company’s JV PRIGIV is expected to contribute meaningfully and scale further.
- →Operational efficiencies and improved product mix are expected to sustain margins near 25%.
- →Growth is driven by volume increases, price rises, and product mix improvements.
- →The bio-based pilot plant and other breakthrough technologies may contribute to future growth beyond the current 5K, 1K plan.
Margin guidance
Category 3- →Privi Speciality Chemicals aims for a revenue target of Rs. 5,000 crore and EBITDA exceeding Rs. 1,000 crore within the next 3-4 years, reflecting about 2x growth.
- →The company targets sustaining EBITDA margins around 24.6% to 25%, supported by operational efficiencies, cost optimization, and improved product mix.
- →Management is confident in maintaining a 20% CAGR over the medium term with similar EBITDA margins.
- →Profit after tax showed robust growth with Rs. 83.2 crore in Q1 FY27 vs. Rs. 61.46 crore in Q1 FY26.
- →Capex of Rs. 850-900 crore planned over the next two years will support Phase-2 and Phase-3 expansions, driving future earnings.
- →Continuous chemistry adoption and new specialty molecules (like Maltol, Ethyl Maltol, Musk T, and furfural-based products) are expected to contribute meaningfully by H2 FY27 onwards.
- →Focus on internal accrual funding with prudent debt levels ensures financial flexibility to support growth.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →Phase-2 CAPEX has commenced; Phase-3 expected around end of this year or early next year.
- →Funding for these phases will primarily come from internal accruals.
- →If needed, borrowing from banks or financial institutions at competitive rates may be considered.
- →Debt-to-EBITDA and debt-to-equity ratios will be closely monitored and maintained well below preferred thresholds.
- →No specific mention of any equity fundraising in the current/future plans.
- →The company maintains a prudent capital structure with a net debt-to-equity ratio of 0.57x as of June 2026, reflecting financial discipline.
Order book
The transcript provided from Privi Speciality Chemicals Limited's Q1 FY27 earnings call does not explicitly mention the current or expected order book or pending orders. However, some related insights include:
- The company is on track to achieve its vision of Rs. 5,000 crores in revenue and Rs. 1,000 crores plus EBITDA over the next 3-4 years.
- Strong demand sustained across key end-user industries supports growth.
- The PRIGIV JV is progressing well, contributing about Rs. 18 crores in revenue with a 14%-15% EBITDA margin.
- The company has a full backlog of contracts with predominantly annual, back-to-back agreements, ensuring stable order flow.
- Capacity expansions from 48,000 to 54,000 metric tons and further to 66,000 metric tons by Sept 2027 are underway to meet increasing demand.
No direct numerical detail is provided about the order book size or pending orders.
Capex plans
Yes- →Ongoing Phase-1 CAPEX to expand production capacity from 48,000 to 54,000 metric tons, expected to be commercialized by September 2026.
- →Planned Phase-2 and Phase-3 CAPEX for multi-specialty aroma chemicals project, targeting capacity expansion to 66,000 metric tons by September 2027.
- →Total CAPEX for FY26–FY28 estimated at around Rs. 850 to 900 crores to complete Phase-2 and Phase-3.
- →Rs. 300 crore CAPEX for existing products slightly delayed, now expected September 2026.
- →Additional Rs. 300 crore CAPEX each for new specialty products including Maltol and Musk T.
- →Joint Venture PRIGIV expanding with an additional Rs. 50 crore equity investment for next-phase expansion.
- →Future demonstration biomass plant (2 tons/day) planned post 5K, 1K plan for pilot testing breakthrough technologies; commercialization expected after 12-15 months of pilot runtime.
- →CAPEX funded mainly through internal accruals with possible bank borrowings, maintaining strong debt-to-equity and debt-to-EBITDA ratios.
How does Privi Speci. rank vs peers in Chemicals & Petrochemicals?
Pro feature1Privi Speci.
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Privi Speci. rank in Chemicals & Petrochemicals?
Compare Privi Speci. against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.